BioLife Solutions Stock
BioLife Solutions, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Roderick de Greef
- Employees
- 155
- Market cap
- $1.9 B
- IPO
- 22/11/1989
BioLife Solutions, Inc. operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. The company is headquartered in Bothell, Washington, in the US. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
BioLife Solutions stock: price history
1D
+0.0%
1W
-0.6%
1M
+9.5%
6M
+95.9%
YTD
+59.7%
1Y
+46.8%
2Y
+61.2%
5Y
+0.6%
10Y
+2,069.1%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~36% weaker price swings than usual
BioLife Solutions stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
BioLife Solutions is a specialized provider of tools and services for the cell and gene therapy industry. The company offers proprietary biopreservation media such as HypoThermosol FRS and CryoStor, which are designed to minimize cell damage during the preservation process. The portfolio also includes automated devices for thawing biological materials as well as intelligent shipping containers for temperature-critical transport of biologics. In addition to product sales, BioLife Solutions generates revenue through rental and storage services. The offering covers the entire value chain, ranging from basic research to commercial production.
- Revenue model
- Hardware sales
- Recurring revenue
- Medium
- Pricing power
- Weak
- Moat
- None
- Moat type
- None
- Capital intensity
- Medium
- Customer concentration
- Unknown
Ask the agents about BioLife Solutions
Analyst assessment of BioLife Solutions
PRICE TARGET LOW
US$31.00
CONSENSUS
US$31.00
MEDIAN
US$31.00
PRICE TARGET HIGH
US$31.00
0
STRONG BUY
12
BUY
6
HOLD
0
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 10/08/2026
BioLife Solutions stock metrics
P/E
37.34
P/B
4.49
EV/EBITDA
194.95
RETURN ON EQUITY
10.7%
NET MARGIN
158.4%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.4%
FLOAT SHARES
42,681,838
AVG. DAILY VOLUME (30D)
1,101,889
Insider transactions (SEC)
Wichterman Troy
Werner Sean
Werner Sean
Berard Todd
Berard Todd
Institutional holders
Dividends & Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about BioLife Solutions stock
What does BioLife Solutions do?
BioLife Solutions, Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Roderick de Greef, the company employs around 155 people.
The IPO was on 22/11/1989; the stock trades on NASDAQ under the ticker BLFS.
What do analysts say about BioLife Solutions stock?
18 analysts rate the stock, the consensus is Buy (as of 10/08/2026).
The average price target is US$31.00, ranging from US$31.00 to US$31.00, with a median of US$31.00.
This is an external assessment, not a statement by Market Jury.
When does BioLife Solutions report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -36% stronger than usual.
Does BioLife Solutions pay a dividend?
No, BioLife Solutions currently does not pay a dividend.
Which stocks are comparable to BioLife Solutions?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get BioLife Solutions stock analyzed?
Clicking "Analyze stock" lets five strategies assess BioLife Solutions against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.